Brief: Blueprint Medicines Says On May 22, After Exceeding Milestone From Sales Of Ayvakit, Lenders Funded Tranche B Delayed Draw Term Loan Of $150.0 Million
24/05/2024 13:31
May 24 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES - ON MAY 22, AFTER EXCEEDING MILESTONE
FROM
SALES OF AYVAKIT, LENDERS FUNDED TRANCHE B DELAYED DRAW TERM
LOAN OF $150.0 MILLION
Source text for Eikon: ID:n0001558370-24-008619
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G